TACSTD2 and neoplasm: Its overexpression may be detected at very early-stages of disease, even during tumor formation, opening new possibility to a prompt therapeutic intervention for TNBC, and posing questions about a universal method for Trop-2 detection. Despite being well-established and validated, the immunohistochemical analysis reported in SG clinical trials differed in terms of antibody selection for Trop-2, ranging from polyclonal (80) to murine mAb (81), mining interpretation and comparison of such data.